全文获取类型
收费全文 | 357篇 |
免费 | 20篇 |
出版年
2023年 | 2篇 |
2022年 | 1篇 |
2021年 | 6篇 |
2020年 | 1篇 |
2019年 | 7篇 |
2018年 | 9篇 |
2017年 | 18篇 |
2016年 | 17篇 |
2015年 | 16篇 |
2014年 | 17篇 |
2013年 | 41篇 |
2012年 | 31篇 |
2011年 | 37篇 |
2010年 | 13篇 |
2009年 | 15篇 |
2008年 | 25篇 |
2007年 | 17篇 |
2006年 | 22篇 |
2005年 | 16篇 |
2004年 | 13篇 |
2003年 | 15篇 |
2002年 | 10篇 |
2001年 | 1篇 |
2000年 | 1篇 |
1999年 | 2篇 |
1998年 | 1篇 |
1997年 | 4篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 3篇 |
1992年 | 2篇 |
1991年 | 2篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1982年 | 2篇 |
1979年 | 1篇 |
1970年 | 2篇 |
排序方式: 共有377条查询结果,搜索用时 15 毫秒
371.
Martina Lepore Signorile Valentina Grossi Simone Di Franco Giovanna Forte Vittoria Disciglio Candida Fasano Paola Sanese Katia De Marco Francesco Claudio Susca Laura Rosa Mangiapane Annalisa Nicotra Gabriella Di Carlo Francesco Dituri Gianluigi Giannelli Giuseppe Ingravallo Gianluca Canettieri Giorgio Stassi Cristiano Simone 《Cell death & disease》2021,12(4)
The prognosis of locally advanced colorectal cancer (CRC) is currently unsatisfactory. This is mainly due to drug resistance, recurrence, and subsequent metastatic dissemination, which are sustained by the cancer stem cell (CSC) population. The main driver of the CSC gene expression program is Wnt signaling, and previous reports indicate that Wnt3a can activate p38 MAPK. Besides, p38 was shown to feed into the canonical Wnt/β-catenin pathway. Here we show that patient-derived locally advanced CRC stem cells (CRC-SCs) are characterized by increased expression of p38α and are “addicted” to its kinase activity. Of note, we found that stage III CRC patients with high p38α levels display reduced disease-free and progression-free survival. Extensive molecular analysis in patient-derived CRC-SC tumorspheres and APCMin/+ mice intestinal organoids revealed that p38α acts as a β-catenin chromatin-associated kinase required for the regulation of a signaling platform involved in tumor proliferation, metastatic dissemination, and chemoresistance in these CRC model systems. In particular, the p38α kinase inhibitor ralimetinib, which has already entered clinical trials, promoted sensitization of patient-derived CRC-SCs to chemotherapeutic agents commonly used for CRC treatment and showed a synthetic lethality effect when used in combination with the MEK1 inhibitor trametinib. Taken together, these results suggest that p38α may be targeted in CSCs to devise new personalized CRC treatment strategies.Subject terms: Cancer stem cells, Colorectal cancer, Post-translational modifications 相似文献
372.
Dario Bongiovanni Melissa Klug Olga Lazareva Simon Weidlich Marina Biasi Simona Ursu Sarah Warth Christian Buske Marina Lukas Christoph D. Spinner Moritz von Scheidt Gianluigi Condorelli Jan Baumbach Karl-Ludwig Laugwitz Markus List Isabell Bernlochner 《Cell death & disease》2021,12(1)
Novel coronavirus disease 2019 (COVID-19) is associated with a hypercoagulable state, characterized by abnormal coagulation parameters and by increased incidence of cardiovascular complications. With this study, we aimed to investigate the activation state and the expression of transmembrane proteins in platelets of hospitalized COVID-19 patients. We investigated transmembrane proteins expression with a customized mass cytometry panel of 21 antibodies. Platelets of 8 hospitalized COVID-19 patients not requiring intensive care support and without pre-existing conditions were compared to platelets of healthy controls (11 donors) with and without in vitro stimulation with thrombin receptor-activating peptide (TRAP). Mass cytometry of non-stimulated platelets detected an increased surface expression of activation markers P-Selectin (0.67 vs. 1.87 median signal intensity for controls vs. patients, p = 0.0015) and LAMP-3 (CD63, 0.37 vs. 0.81, p = 0.0004), the GPIIb/IIIa complex (4.58 vs. 5.03, p < 0.0001) and other adhesion molecules involved in platelet activation and platelet–leukocyte interactions. Upon TRAP stimulation, mass cytometry detected a higher expression of P-selectin in COVID-19 samples compared to controls (p < 0.0001). However, we observed a significantly reduced capacity of COVID-19 platelets to increase the expression of activation markers LAMP-3 and P-Selectin upon stimulation with TRAP. We detected a hyperactivated phenotype in platelets during SARS-CoV-2 infection, consisting of highly expressed platelet activation markers, which might contribute to the hypercoagulopathy observed in COVID-19. In addition, several transmembrane proteins were more highly expressed compared to healthy controls. These findings support research projects investigating antithrombotic and antiplatelet treatment regimes in COVID-19 patients, and provide new insights on the phenotypical platelet expression during SARS-CoV-2 infection.Subject terms: Mechanisms of disease, Viral infection 相似文献
373.
374.
Sophie Lévy-Schil Laurent Debussche Sylvie Rigault Fabienne Soubrier Fabrice Bacchetta Delphine Lagneaux Josiane Schleuniger Francis Blanche Joël Crouzet Jean-François Mayaux 《Applied microbiology and biotechnology》1993,38(6):755-762
The effect of the overexpression of the bioABFCD operon on the biotin biosynthetic pathway was investigated in an Escherichia coli K12 bioR mutant with a chromosomal deletion for the biotin operon. When transformed with a multicopy number plasmid containing bioABFCD, this strain synthetized 10,000 times more biotin than a wild-type E. coli strain. In order to further increase biotin production, the bioA and bioB operons were subcloned into plasmids with stronger promoters and in some cases optimal ribosome binding sites. The new constructions led to the accumulation of large amounts of soluble Bio proteins (although not BioC) but did not improve biotin production. In all the constructed strains, BioA, BioD, and BioB activities were greatly amplified but these activitie did not correlate with the level of protein syntthesis. These strains accumulated only low levels of vitamers, auggesting that the major limiting step for higher biotin production occurs upstream from the first intermediate of the Bio pathway we assayed (7,keto-8-aminopelargonic acid). As BioC overproduction was shown to impair cell growth, we could not determine if this early step of pathway was limiting.
Correspondence to: S. Lévy-Schil 相似文献
375.
Giulia Santamaria Edoardo Brandi Pietro La Vitola Federica Grandi Giovanni Ferrara Francesca Pischiutta Gloria Vegliante Elisa R. Zanier Francesca Re Antonio Uccelli Gianluigi Forloni Nicole Kerlero de Rosbo Claudia Balducci 《Cell death and differentiation》2021,28(1):203
The multiplicity of systems affected in Alzheimer’s disease (AD) brains calls for multi-target therapies. Although mesenchymal stem cells (MSC) are promising candidates, their clinical application is limited because of risks related to their direct implantation in the host. This could be overcome by exploiting their paracrine action. We herein demonstrate that in vivo systemic administration of secretome collected from MSC exposed in vitro to AD mouse brain homogenates (MSC-CS), fully replicates the cell-mediated neuroreparative effects in APP/PS1 AD mice. We found a complete but transient memory recovery by 7 days, which vanished by 14 days, after a single MSC-CS intravenous administration in 12-month or 22–24-month-old mice. Treatment significantly reduced plaque load, microglia activation, and expression of cytokines in astrocytes in younger, but not aged, mice at 7 days. To optimize efficacy, we established a sustained treatment protocol in aged mice through intranasal route. Once-weekly intranasal administration of MSC-CS induced persistent memory recovery, with dramatic reduction of plaques surrounded by a lower density of β-amyloid oligomers. Gliosis and the phagocytic marker CD68 were decreased. We found a higher neuronal density in cortex and hippocampus, associated with a reduction in hippocampal shrinkage and a longer lifespan indicating healthier conditions of MSC-CS-treated compared to vehicle-treated APP/PS1 mice. Our data prove that MSC-CS displays a great multi-level therapeutic potential, and lay the foundation for identifying the therapeutic secretome bioreactors leading to the development of an efficacious multi-reparative cocktail drug, towards abrogating the need for MSC implantation and risks related to their direct use.Subject terms: Neural ageing, Neurological disorders, Inflammation 相似文献
376.
377.